AR024537A1 - Combinacion sinergica para el tratamiento de enfermedades mediadas virales - Google Patents
Combinacion sinergica para el tratamiento de enfermedades mediadas viralesInfo
- Publication number
- AR024537A1 AR024537A1 ARP000100819A ARP000100819A AR024537A1 AR 024537 A1 AR024537 A1 AR 024537A1 AR P000100819 A ARP000100819 A AR P000100819A AR P000100819 A ARP000100819 A AR P000100819A AR 024537 A1 AR024537 A1 AR 024537A1
- Authority
- AR
- Argentina
- Prior art keywords
- mediumed
- viral
- diseases
- treatment
- synergic combination
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/19—Cytokines; Lymphokines; Interferons
- A61K38/21—Interferons [IFN]
- A61K38/212—IFN-alpha
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/19—Cytokines; Lymphokines; Interferons
- A61K38/21—Interferons [IFN]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Virology (AREA)
- Epidemiology (AREA)
- Immunology (AREA)
- Engineering & Computer Science (AREA)
- Gastroenterology & Hepatology (AREA)
- Zoology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Communicable Diseases (AREA)
- Molecular Biology (AREA)
- Oncology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
Las infecciones por falvivirus y rhabdovirus pueden ser tratadas administrando un interferon tal como el interferon a 2, el interferon a 8 o un interferonb y al menos un compuesto seleccionado de los nucleosidos cíclicos de 5 miembros, los compuestosmicofenolicos y los derivados de la imidazola,amidoadamantanos y 2,4-diaminopirimidinas.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US12193199P | 1999-02-26 | 1999-02-26 | |
US18106800P | 2000-02-08 | 2000-02-08 |
Publications (1)
Publication Number | Publication Date |
---|---|
AR024537A1 true AR024537A1 (es) | 2002-10-16 |
Family
ID=26819981
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
ARP000100819A AR024537A1 (es) | 1999-02-26 | 2000-02-25 | Combinacion sinergica para el tratamiento de enfermedades mediadas virales |
Country Status (8)
Country | Link |
---|---|
EP (1) | EP1154787B1 (es) |
AR (1) | AR024537A1 (es) |
AT (1) | ATE301468T1 (es) |
AU (1) | AU3501100A (es) |
CA (1) | CA2362877A1 (es) |
DE (1) | DE60021857T2 (es) |
MY (1) | MY125300A (es) |
WO (1) | WO2000050064A2 (es) |
Families Citing this family (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1368887A (zh) * | 1999-08-13 | 2002-09-11 | 弗·哈夫曼-拉罗切有限公司 | 与PEG-IFN-α结合的霉酚酸酯Mofetil |
EP1296690A2 (en) * | 2000-02-18 | 2003-04-02 | Shire Biochem Inc. | METHOD FOR THE TREATMENT OR PREVENTION OF i FLAVIVIRUS /i INFECTIONS USING NUCLEOSIDE ANALOGUES |
JP2002201141A (ja) | 2000-10-27 | 2002-07-16 | Hayashibara Biochem Lab Inc | 蛋白質合成抑制遺伝子の発現増強剤 |
AU2004224575A1 (en) * | 2003-03-28 | 2004-10-07 | Pharmasset Ltd. | Compounds for the treatment of flaviviridae infections |
CN115466710A (zh) * | 2021-06-11 | 2022-12-13 | 舒泰神(北京)生物制药股份有限公司 | 一种获得无病毒细胞系的方法及其所获得的无病毒细胞系 |
Family Cites Families (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB1135898A (es) * | ||||
US4975434A (en) * | 1986-05-27 | 1990-12-04 | The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services | Antiviral and anticancer cyclopentenyl cytosine |
CA1317588C (en) * | 1988-02-29 | 1993-05-11 | Tohru Ueda | Imidazole derivatives, process for production thereof, and use thereof |
US5676942A (en) * | 1992-02-10 | 1997-10-14 | Interferon Sciences, Inc. | Composition containing human alpha interferon species proteins and method for use thereof |
US5380879A (en) * | 1994-02-18 | 1995-01-10 | Syntex (U.S.A.) Inc. | Derivatives of mycophenolic acid |
AU5157998A (en) * | 1996-11-01 | 1998-05-29 | Thomas Najarian | Methods and compositions for treatment of hepatitis c infection |
WO2000015210A2 (en) * | 1998-09-14 | 2000-03-23 | Vertex Pharmaceuticals Incorporated | Use of mycophenol acid and its derivatives for the treatment of virus diseases |
-
2000
- 2000-02-24 MY MYPI20000690A patent/MY125300A/en unknown
- 2000-02-25 WO PCT/US2000/004699 patent/WO2000050064A2/en active IP Right Grant
- 2000-02-25 AR ARP000100819A patent/AR024537A1/es unknown
- 2000-02-25 DE DE60021857T patent/DE60021857T2/de not_active Expired - Fee Related
- 2000-02-25 AU AU35011/00A patent/AU3501100A/en not_active Abandoned
- 2000-02-25 CA CA002362877A patent/CA2362877A1/en not_active Abandoned
- 2000-02-25 AT AT00913596T patent/ATE301468T1/de not_active IP Right Cessation
- 2000-02-25 EP EP00913596A patent/EP1154787B1/en not_active Expired - Lifetime
Also Published As
Publication number | Publication date |
---|---|
EP1154787B1 (en) | 2005-08-10 |
MY125300A (en) | 2006-07-31 |
WO2000050064A3 (en) | 2001-04-05 |
DE60021857D1 (de) | 2005-09-15 |
AU3501100A (en) | 2000-09-14 |
DE60021857T2 (de) | 2006-06-01 |
EP1154787A2 (en) | 2001-11-21 |
WO2000050064A2 (en) | 2000-08-31 |
CA2362877A1 (en) | 2000-08-31 |
ATE301468T1 (de) | 2005-08-15 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
UY29868A1 (es) | Nucleocidos 4 modificados como agentes antivirales | |
BRPI0415883A (pt) | compostos e composições de nucleosìdeo para o tratamento de infecções virais | |
UY27466A1 (es) | Métodos y composiciones para el tratamiento de hepatitis c virus con 4'-modificaciones nucleosides | |
BR0309581A (pt) | Derivados de nucleosìdeo para tratamento de infecção por vìrus de hepatite c | |
UY28084A1 (es) | Derivados antivirales de nucleosidos | |
DK1265889T3 (da) | Lægemidler imod virussygdomme | |
ATE249219T1 (de) | Antivirale verbindungen | |
ECSP077412A (es) | Derivados de indol tetracíclicos como agentes antivíricos | |
ECSP055801A (es) | Compuestos benzofuránicos, composiciones y métodos para el tratamiento y profilaxis de infecciones virales de hepatitis c y enfermedades asociadas | |
TW200633995A (en) | Andrographolide derivatives to treat viral infections | |
EA200500584A1 (ru) | Нуклеозидные производные для лечения инфекционных заболеваний, вызванных вирусом гепатита c | |
DE60215157D1 (de) | Verwendungen von antiviralen nucleosid-derivaten zur herstellung eines medikaments zur behandlung von hepatitis c infektionen | |
CY1106679T1 (el) | Αζαδικυκλικες ετεροκυκλικες ενωσεις ως τροποποιητες κανναβινοειδους υποδοχεα | |
EA200201279A1 (ru) | Способы и композиции для лечения вирусного гепатита c | |
EA201000643A1 (ru) | Замещенное производное этилендиамина для лечения микобактериальных заболеваний и фармацевтическая композиция на его основе | |
MX2022016405A (es) | Análogos de nucleósido de 1¿-ciano y usos de estos. | |
NO20034204D0 (no) | Farmasöytiske kombinasjoner til behandling av kreft | |
CO4810375A1 (es) | Derivados de 9-amino-3-ceto eritromicina | |
PA8556901A1 (es) | Nuevos derivados de piperazina | |
EA200000836A1 (ru) | Применение n-замещенных 1,5-дидезокси-1,5-имино-d-глюцитных производных для лечения инфекций, вызываемых вирусами гепатита | |
MXPA06000418A (es) | Derivados de ariltiourea sustituida utiles como inhibidores de duplicacion viral. | |
DE60101223D1 (de) | Antivirale pyrimidin nucleoside derivate | |
AR025929A1 (es) | Compuestos para el tratamiento de enfermedades mediadas por virus | |
ES2108969T3 (es) | Utilizacion de analogos de didesoxinucleosidos en el tratamiento de infecciones virales. | |
AR024537A1 (es) | Combinacion sinergica para el tratamiento de enfermedades mediadas virales |